A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Intepirdine (Primary)
- Indications Lewy body disease
- Focus Registrational; Therapeutic Use
- Acronyms HEADWAY-DLB
- Sponsors Axovant Sciences
- 02 Nov 2017 According to an Axovant Sciences media release, the company is re-evaluating endpoints of this trial and plans a discussion with the U.S. FDA to determine registration pathway. Top-line data are expected to be reported in January 2018.
- 27 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
- 27 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.